OptiMega-3® with Vitamin D3

OptiMega-3® with Vitamin D3

Pharmaceutical Grade

200 mL ( SKU: 9370, NPN: 80073481 )

Benefits

  • Optimal 2:1 ratio EPA to DHA, providing convenient once daily dosing
  • Clinical dosing of 1500 mg EPA and 750 mg DHA in triglyceride form, and 1000 IU Vitamin D3 per teaspoon
  • Pharmaceutical grade omega-3 blend, USP certified verifying the quality and consistency of the fish oil
  • Free of lipid peroxides and environmental pollutants, including heavy metals, pesticides, dioxins, PCBs, and other harmful compounds
  • Highly bioavailable and delicious lemon flavour

Feature Summary

Omega-3 fatty acids from fish oil and vitamin D are among the most powerful nutrients for improving overall health, and are also among the most commonly deficient. EPA and DHA improve a number of cardiovascular risk factors including lowering of atherosclerotic burden, reducing triglyceride levels and blood pressure, and improving platelet and vascular function.1-3 They have been associated with a reduced incidence of cardiovascular events, cardiac death and coronary events, especially in those at high risk,as well as lower all-cause mortality, sudden death, myocardial infarction, and stroke.4-9 EPA and DHA support cognitive function through multiple mechanisms, as they are indispensable to neuronal membranes, with lower levels found to be not only a marker for neurological disease but also a risk factor for cognitive impairment.10,11

Vitamin D has also been shown to modify cardiovascular risk, and reduce the risk of several cancers, autoimmune disease, osteoporotic fractures, and overall mortality.12-16 Lower levels have been linked to neurodegenerative disease, cognitive decline, and memory.17-20 EPA and DHA combined with vitamin D are likely to have synergistic benefits for improving overall wellness, as well as for preventing and treating a wide variety of cardiovascular, neurological, inflammatory and autoimmune conditions.21

Medicinal Ingredients

Serving Size: 5 ml
Servings per Container: 40

Each Teaspoon (5 ml) Contains:
Fish Oil (Anchovy, Sardine and/or Mackerel)................................................................. 4500 mg
Omega-3 Fatty Acids...................................................................................................2630 mg
Eicosapentaenoic Acid (EPA) ................................................................................1500 mg
Docosahexaenoic Acid (DHA)..................................................................................750 mg
Vitamin D3 (Cholecalciferol) ...........................................................................................1000 IU (25 mcg)

Non-Medicinal Ingredients

Lemon flavour, lemon peel essential oil, tocopherols, monk fruit extract.

Allergens:

Contains no artificial colours, preservatives, or sweeteners; no dairy, starch, sugar, wheat, gluten, yeast, soy, corn, egg, shellfish, salt, tree nuts, or GMOs. Sealed for your protection. Do not use if seal is broken. Refrigerate after opening. Store in airtight container, protected from light.

Contraindications

Both benefit and risk has been documented for those at risk of or being treated for cardiac arrhythmias, with close supervision indicated.22 Supplemental vitamin D should be used with caution in those with sarcoidosis, lymphoma, tuberculosis, hypercalcemia or renal impairment.23

Drug Interactions

The antihypertensive effect of fish oil and/or vitamin D may potentially reduce the need or dosage for blood pressure medications, and patients should be closely monitored. Because fish oil has an antithrombotic effect, caution is advised for those on anticlotting, antiplatelet or anticoagulant medications, or those at high risk of bleeding.24 At doses greater than 3 g per day, hyperglycemia has been observed in diabetics and those with hypertriglyceridemia and close monitoring of patients onantidiabetic medication is recommended. Vitamin D may increase the risk for hypercalcemia when taken with a thiazide medication(diuretic).25 Benefit has been shown when fish oil is taken with statins, SSRIs, anticonvulsant and cytotoxic medications.26,27

  1. Pischon T, Hankinson SE, Hotamisligil GS, et al. Habitual dietary intake of omega-3 and omega-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003 Jul 15;108(2):155-60.
  2. Swanson D, Block R, Mousa SA. Omega-3 fatty acids EPA and DHA: health benefits throughout life. Adv Nutr. 2012;3:1-7.
  3. Miller PE, Van Elswyk M, Alexander DD. Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and blood pressure: a meta-analysis of randomized controlled trials. Am J Hypertens. 2014 Jul;27(7):885-96. doi:10.1093/ajh/hpu024.
  4. Delgado-Lista J, Perez-Martinez P, Lopez-Miranda J, et al. Long chain omega-3 fatty acids and cardiovascular disease:a systematic review. Br J Nutr. 2012 Jun;107 Suppl 2:S201-13. doi:10.1017/S0007114512001596.
  5. Wang C, Harris WS, Chung M, et al. n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid,benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006 Jul;84(1):5-17.
  6. Saito Y, Yokoyama M, Origasa H, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis. 2008 Sep;200(1):135-40.
  7. Pottala JV, Garg S, Cohen BE, et al. Blood eicosapentaenoic and docosahexaenoic acids predict all-cause mortality in patients with stable coronary heart disease: the Heart and Soul study. Circ Cardiovasc Qual Outcomes. 2010Jul;3(4):406-12.
  8. Casula M, Soranna D, Catapano AL, et al. Atheroscler Suppl. 2013 Aug;14(2):243-51.
  9. Tanaka K, Ishikawa Y, Yokoyama M, et al. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008 Jul;39(7):2052-8.
  10. Lin PY, Chiu CC, Huang SY, Su KP. A meta-analytic review of polyunsaturated fatty acid compositions in dementia. J Clin Psychiatry. 2012 Sep;73(9):1245-54.
  11. Dyall SC. Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA. Front Aging Neurosci. 2015 Apr 21;7:52.
  12. Muscogiuri G, Sorice GP, Ajjan R, Mezza T, Pilz S, Prioletta A, Scragg R, Volpe SL, Witham MD, Giaccari A. Can vitamin D deficiency cause diabetes and cardiovascular diseases? Present evidence and future perspectives. Nutr Metab Cardiovasc Dis. 2012 Feb;22(2):81-7.
  13. Fletcher JM, Basdeo SA, Allen AC, Dunne PJ. Therapeutic use of vitamin D and its analogues in autoimmunity. Recent Pat Inflamm Allergy Drug Discov. 2012 Jan;6(1):22-34.
  14. Baz-Hecht M, Goldfine AB. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes. 2010 Apr;17(2):113-9.
  15. Zittermann A, Prokop S. The role of vitamin D for cardiovascular disease and overall mortality. Adv Exp Med Biol.2014;810:106-19.
  16. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014 Apr 1;348:g1903.doi:10.1136/bmj.g1903.
  17. Mokry LE, Ross S, Morris JA, et al. Genetically decreased vitamin D and risk of Alzheimer disease. Neurology. 2016 Dec 13;87(24):2567-2574.
  18. Gatto NM, Paul KC, Sinsheimer JS, et al. Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson’s disease. J Neurol Sci. 2016 Nov 15;370:100-106.
  19. Llewellyn DJ, Lang IA, Langa KM, et al. Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med. 2010 Jul 12;170(13):1135-41.
  20. Assmann KE, Touvier M, Andreeva VA, et al. Midlife plasma vitamin D concentrations and performance in different cognitive domains assessed 13 years later. Br J Nutr. 2015 May 28;113(10):1628-37.
  21. Manson JE, Bassuk SS, et al. The VITtamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials. 2012 Jan;33(1):159-71.
  22. Kromhout D, de Goede J. Update on cardiometabolic health effects of ?-3 fatty acids. Curr Opin Lipidol. 2014 Feb;25(1):85-90.
  23. Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with sarcoidosis. J Am Acad Dermatol. 2011 Apr;64(4):795-6.
  24. Harris WS. Expert opinion: omega-3 fatty acids and bleeding-cause for concern? Am J Cardiol. 2007 Mar19;99(6A):44C-46C.
  25. Boulard JC, Hanslik T, Alterescu R, Baglin A. [Symptomatic hypercalcemia after vitamin D-thiazide diuretics combination.Two cases in elderly women]. Presse Med. 1994 Jan 22;23(2):96.
  26. Toyama K, Nishioka T, Isshiki A, et al. Eicosapentaenoic Acid combined with optimal statin therapy improves endothelial dysfunction in patients with coronary artery disease. Cardiovasc Drugs Ther. 2014 Feb;28(1):53-9.
  27. Mischoulon D, Freeman MP. Omega-3 fatty acids in psychiatry. Psychiatr Clin North Am. 2013 Mar;36(1):15-23.